BRAF and skin neoplasm: The addition of the inhibition of the downstream effector MEK improved progression-free survival (PFS) from 6.2–8.8 months to 9.9–11.4 months compared to BRAF-i alone [8,9], also reducing the secondary skin cancers rate (7% vs. 19%) [10].